Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis

Clinical Chemistry

Volumn 53, Issue 9, 2007, Pages 1609-1614

  Zhong, Xiao Yan ^a   Von Mühlenen, Ines ^b   Li, Ying ^a   Kang, Anjeung ^a   Gupta, Anurag Kumar ^a   Tyndall, Alan ^b   Holzgreve, Wolfgang ^a   Hahn, Sinuhe ^a   Hasler, Paul ^b,c,d  

^a UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Rheumaklinik   (Switzerland)

^d Rheumaklinik   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL FREE SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DNA; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; MIDDLE AGED; PILOT PROJECTS; PROTEIN BINDING;

ANIMALIA;

EID: 34548331348     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.084509     Document Type: Article

References (36)

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
2. Dayer JM. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 2002;69:123-32.
3. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
4. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
5. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? II. T cell-independent mechanisms from beginning to end. Arthritis Rheum 2002;46:298-308.
6. Kim HJ, Berek C. B cells in rheumatoid arthritis. Arthritis Res 2000;2:126-31.
7. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
8. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
9. Maccioni M, Zeder-Lutz G, Huang H, Ebel C, Gerber P, Hergueux J, et al. Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med 2002;195:1071-7.
10. Tetlow LC, Woolley DE. Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion. Ann Rheum Dis 1995;54:549-55.
11. Matsumoto I, Lee DM, Goldbach-Mansky R, Sumida T, Hitchon CA, Schur PH, et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum 2003;48:944-54.
12. Schaller M, Stohl W, Tan SM, Benoit VM, Hilbert DM, Ditzel HJ. Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis. Ann Rheum Dis 2005;64:743-9.
13. Monach PA, Benoist C, Mathis D. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease. Adv Immunol 2004;82:217-48.
14. Solomon S, Kassahn D, Illges H. The role of the complement and the Fc gamma R system in the pathogenesis of arthritis. Arthritis Res Ther 2005;7:129-35.
15. Christian CL, Elkon KB. Autoantibodies to intracellular proteins: clinical and biologic significance. Am J Med 1986;80:53-61.
16. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Zhong XY, Laivuori H, Livingston JC, Ylikorkala O, Sibai BM, Holzgreve W, et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol 2001;184:414-9.
19. Zhong XY, Holzgreve W, Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy 2002;21:77-83.
20. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999;64:218-24.
21. Anker P, Stroun M. Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease. Leukemia 2001;15:289-91.
22. Bret L, Lule J, Alary C, Appolinaire-Pilipenko S, Pourrat JP, Fournie GJ. Quantitation of blood plasma DNA as an index of in vivo cytotoxicity. Toxicology 1990;61:283-92.
23. Hahn S, Huppertz B, Holzgreve W. Fetal cells and cell free fetal nucleic acids in maternal blood: new tools to study abnormal placentation? Placenta 2005;26:515-26.
24. Holdenrieder S, Stieber P, Forg T, Kuhl M, Schulz L, Busch M, et al. Apoptosis in serum of patients with solid tumours. Anticancer Res 1999;19:2721-4.
25. Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 2001;41:276-82.
26. Garcia-Olmo D, Garcia-Olmo DC, Ontanon J, Martinez E, Vallejo M. Tumor DNA circulating in the plasma might play a role in metastasis: the hypothesis of the genometastasis. Histol Histopathol 1999;14:1159-64.
27. Zhong XY, Burk MR, Troeger C, Kang A, Holzgreve W, Hahn S. Fluctuation of maternal and fetal free extracellular circulatory DNA in maternal plasma. Obstet Gynecol 2000;96:991-6.
28. Steinman CR. Free DNA in serum and plasma from normal adults. J Clin Invest 1975;56:512-5.
29. Karsh J, Halbert SP, Anken M, Klima E, Steinberg AD. Anti-DNA, anti-deoxyribonucleoprotein and rheumatoid factor measured by ELISA in patients with systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis. Int Arch Allergy Appl Immunol 1982;68:60-9.
30. Rauch J, Tannenbaum H, Straaton K, Massicotte H, Wild J. Human-human hybridoma autoantibodies with both anti-DNA and rheumatoid factor activities. J Clin Invest 1986;77:106-12.
31. Schwartz RS, Stollar BD. Origins of anti-DNA autoantibodies. J Clin Invest 1985;75:321-7.
32. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-5.
33. Gupta AK, Hasler P, Holzgreve W, Gebhardt S, Hahn S. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum Immunol 2005;66:1146-54.
34. Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006;443:998-1002.
35. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
36. Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 2003;30:2557-62.